These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 32660565)

  • 1. CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation.
    Shim KH; Kang MJ; Suh JW; Pyun JM; Ryoo N; Park YH; Youn YC; Jang JW; Jeong JH; Park KW; Choi SH; Suk K; Lee HW; Ko PW; Lee CN; Lim TS; An SSA; Kim S;
    Alzheimers Res Ther; 2020 Jul; 12(1):83. PubMed ID: 32660565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
    Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J
    Acta Neuropathol; 2013 Nov; 126(5):683-97. PubMed ID: 23812319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
    Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
    Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
    Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
    BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cerebrospinal fluid α-synuclein with total and phospho-tau
    Vergallo A; Bun RS; Toschi N; Baldacci F; Zetterberg H; Blennow K; Cavedo E; Lamari F; Habert MO; Dubois B; Floris R; Garaci F; Lista S; Hampel H; ;
    Alzheimers Dement; 2018 Dec; 14(12):1623-1631. PubMed ID: 30055132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.
    Cicognola C; Hansson O; Scheltens P; Kvartsberg H; Zetterberg H; Teunissen CE; Blennow K
    Alzheimers Res Ther; 2021 Feb; 13(1):38. PubMed ID: 33557920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Karikari TK; Emeršič A; Vrillon A; Lantero-Rodriguez J; Ashton NJ; Kramberger MG; Dumurgier J; Hourregue C; Čučnik S; Brinkmalm G; Rot U; Zetterberg H; Paquet C; Blennow K
    Alzheimers Dement; 2021 May; 17(5):755-767. PubMed ID: 33252199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.
    Shim KH; Kang MJ; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2022 Dec; 14(1):201. PubMed ID: 36587215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay.
    Bellomo G; Toja A; Paolini Paoletti F; Ma Y; Farris CM; Gaetani L; Salvadori N; Chiasserini D; Wojdaƚa AL; Concha-Marambio L; Parnetti L
    Alzheimers Dement; 2024 Apr; 20(4):2444-2452. PubMed ID: 38323747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia.
    Diaz-Lucena D; Escaramis G; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Santana I; Del Rio JA; Martí E; Ferrer I; Baldeiras I; Zerr I; Llorens F
    J Neurol; 2020 Sep; 267(9):2567-2581. PubMed ID: 32372181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.